EQRx, Inc. (EQRXW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
EQRx, Inc. (EQRXW) trades at $0.05 with AI Score 47/100 (Grade C). EQRx, Inc. is a pharmaceutical company focused on developing and commercializing innovative medicines for oncology and immune-inflammatory diseases. Market cap: $1.14B, Sector: Healthcare.
Last analyzed: Mar 15, 2026Analyst Coverage for EQRXW: EQRXW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EQRXW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EQRXW: the 1 perspectives are evenly split.
EQRx, Inc. (EQRXW) Healthcare & Pipeline Overview
EQRx, Inc. is a biotechnology company developing oncology and immune-inflammatory disease treatments, including Aumolertinib and Sugemalimab. Founded in 2020, EQRx aims to provide innovative medicines at accessible prices, partnering with companies like Exscientia and AbCellera Biologics. The company operates in the competitive US pharmaceutical market.
What Is the Investment Thesis for EQRXW?
EQRx presents a compelling investment thesis centered on its pipeline of oncology and immune-inflammatory disease treatments. Key value drivers include the potential approval and commercialization of Aumolertinib and Sugemalimab, addressing significant markets in NSCLC. The company's commitment to affordable pricing could drive market penetration and adoption. With a market capitalization of $1.14 billion and a P/E ratio of 5.40, EQRx's valuation reflects both its potential and the inherent risks of pharmaceutical development. Upcoming clinical trial results and regulatory milestones represent key catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
EQRXW Key Highlights
- Market capitalization of $1.14 billion, reflecting investor valuation of its drug pipeline.
- P/E ratio of 5.40, suggesting potential undervaluation compared to industry peers.
- Focus on oncology and immune-inflammatory diseases, areas with significant unmet medical needs.
- Partnerships with Exscientia and AbCellera Biologics Inc. enhance research and development capabilities.
- Pipeline includes Aumolertinib and Sugemalimab, targeting large NSCLC market segments.
Who Are EQRXW's Competitors?
EQRXW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $915.89M | 71 |
| CBIO Crescent Biopharma, Inc. | $18.80 | +2.54% | 519M | 61 |
| CINC CinCor Pharma, Inc. | $29.06 | +0.00% | $1.27B | 47 |
| CTIC CTI BioPharma Corp. | $9.10 | +0.06% | $1.20B | 56 |
| ETHZ ETHZ | $3.53 | +0.00% | 57M | 52 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.02 | +0.61% | $1.60B | 79 |
| ANAB AnaptysBio, Inc. | $54.24 | +4.11% | $2.34B | 79 |
| ABCL AbCellera Biologics Inc. | $5.23 | -0.76% | $1.60B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EQRXW's Key Strengths?
- Innovative drug pipeline targeting significant unmet medical needs.
- Focus on affordability, potentially increasing market access.
- Strategic partnerships enhancing research and development capabilities.
- Experienced management team with expertise in pharmaceutical development.
What Are EQRXW's Weaknesses?
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Limited commercialization experience compared to established pharmaceutical companies.
- Potential competition from existing therapies and biosimilars.
- Dependence on partnerships for research and development.
What Could Drive EQRXW Stock Higher?
- Clinical trial results for Aumolertinib in EGFR-mutated NSCLC.
- Regulatory submissions for Sugemalimab in stage III and IV NSCLC.
- Advancement of Lerociclib clinical trials for HR+/HER2- breast cancer.
- Progress in the development of EQ176 for liver cancer treatment.
What Are the Key Risks for EQRXW?
- Clinical trial failures or delays for key drug candidates.
- Regulatory hurdles and potential rejection of drug submissions.
- Competition from established pharmaceutical companies with greater resources.
- Pricing pressures and reimbursement challenges in the healthcare market.
What Are the Growth Opportunities for EQRXW?
- Aumolertinib Approval and Commercialization: Aumolertinib, an EGFR inhibitor for EGFR-mutated NSCLC, represents a significant growth opportunity. The NSCLC market is substantial, with a global market size estimated at billions of dollars. Successful clinical trials and regulatory approval could drive significant revenue growth for EQRx. The timeline for potential approval is dependent on ongoing clinical trials and regulatory review processes. EQRx's competitive advantage lies in its focus on affordability and potential for improved efficacy.
- Sugemalimab Expansion in NSCLC: Sugemalimab, an anti-PD-L1 antibody, targets stage III and IV NSCLC. This represents another key growth area, given the high prevalence of NSCLC globally. Expansion into additional markets and indications could further boost revenue. The timeline for expansion depends on clinical trial results and regulatory approvals. EQRx's competitive advantage is its potential to offer a cost-effective alternative to existing PD-L1 inhibitors.
- Lerociclib Development for Breast Cancer: Lerociclib, a CDK4/6 inhibitor, is being developed for HR+/HER2- breast cancer, a large and growing market. Successful clinical trials and regulatory approval could lead to significant market share. The timeline for potential approval is contingent on clinical trial outcomes and regulatory review. EQRx's focus on affordability could provide a competitive edge in this market.
- EQ176 Advancement in Liver Cancer: EQ176, an anti-PD-1 antibody, is under development for liver cancer treatment. Liver cancer represents a significant unmet medical need, and successful development of EQ176 could drive substantial growth. The timeline for advancement depends on clinical trial progress and regulatory approvals. EQRx's competitive advantage lies in its potential to offer a novel treatment option.
- Strategic Partnerships and Acquisitions: EQRx can pursue growth through strategic partnerships and acquisitions to expand its pipeline and capabilities. Collaborations with other biotechnology companies or acquisitions of promising drug candidates could accelerate growth and diversify its portfolio. The market for partnerships and acquisitions in the biotechnology sector is active, providing numerous opportunities for EQRx to enhance its competitive position.
What Opportunities Does EQRXW Have?
- Expansion into new markets and indications.
- Acquisition of additional drug candidates or technologies.
- Collaboration with healthcare providers and payers to improve access.
- Development of personalized medicine approaches.
What Threats Does EQRXW Face?
- Clinical trial failures or delays.
- Regulatory hurdles and changing healthcare policies.
- Competition from established pharmaceutical companies with greater resources.
- Pricing pressures and reimbursement challenges.
What Are EQRXW's Competitive Advantages?
- Proprietary drug pipeline with patent protection.
- Focus on affordability, potentially increasing market access.
- Strategic partnerships enhancing research and development.
- Expertise in oncology and immune-inflammatory diseases.
What Does EQRXW Do?
EQRx, Inc., established in 2020 and headquartered in Cambridge, Massachusetts, is a pharmaceutical company dedicated to creating and delivering innovative medicines, particularly in the fields of oncology and immune-inflammatory diseases. The company's mission is to develop high-quality therapeutics and make them more accessible and affordable to patients. EQRx's product pipeline features several promising drug candidates, including Aumolertinib, an EGFR inhibitor targeting EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for stage III and IV NSCLC; Lerociclib, a CDK4/6 inhibitor designed to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1 antibody under development for liver cancer treatment. These assets reflect the company's focus on addressing significant unmet medical needs in critical disease areas. EQRx has also established strategic partnerships with companies like Exscientia and AbCellera Biologics Inc. to enhance its research and development capabilities and accelerate the discovery and development of new medicines. The company operates primarily in the United States.
What Products and Services Does EQRXW Offer?
- Develop medicines for oncology and immune-inflammatory diseases.
- Focus on creating high-quality therapeutics at accessible prices.
- Advance a pipeline of drug candidates, including Aumolertinib and Sugemalimab.
- Target non-small cell lung cancer (NSCLC) with multiple therapies.
- Develop treatments for breast cancer and liver cancer.
- Partner with companies like Exscientia and AbCellera Biologics Inc. for research and development.
How Does EQRXW Make Money?
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of approved medications.
- Partner with other companies for research and development.
- Focus on oncology and immune-inflammatory diseases.
What Industry Does EQRXW Operate In?
EQRx operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for oncology and immune-inflammatory disease treatments is substantial and growing, driven by aging populations and increasing disease prevalence. EQRx aims to differentiate itself by offering innovative medicines at more accessible prices. Competitors include established pharmaceutical companies and other biotechnology firms developing similar therapies. The industry is also influenced by trends such as personalized medicine, immunotherapy, and gene editing.
Who Are EQRXW's Key Customers?
- Patients with cancer and immune-inflammatory diseases.
- Healthcare providers who prescribe EQRx medications.
- Hospitals and clinics that administer EQRx treatments.
- Pharmacy benefit managers (PBMs) who negotiate drug prices.
EQRXW Latest News
No recent news available for EQRXW.
EQRXW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EQRXW.
Price Targets
Wall Street price target analysis for EQRXW.
EQRXW MoonshotScore
What does this score mean?
The MoonshotScore rates EQRXW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Alexis A. Borisy A.M.
Chief Executive Officer
Alexis A. Borisy is a seasoned biotechnology entrepreneur and executive. He has a strong track record of founding and leading successful biotech companies. His career includes roles in venture capital and drug development. He holds an A.M. degree, reflecting his academic background and expertise in the life sciences. He has extensive experience in building and scaling innovative healthcare companies.
Track Record: Under Alexis A. Borisy's leadership, EQRx has focused on developing a pipeline of oncology and immune-inflammatory disease treatments. He has overseen the company's strategic partnerships and efforts to make innovative medicines more accessible. His leadership is focused on driving the company's mission to deliver high-quality therapeutics at affordable prices. He manages 216 employees.
What Investors Ask About EQRx, Inc. (EQRXW) — Healthcare
What does EQRx, Inc. do?
EQRx, Inc. is a pharmaceutical company focused on developing and commercializing innovative medicines for oncology and immune-inflammatory diseases. The company's mission is to create high-quality therapeutics and make them more accessible and affordable to patients. EQRx is advancing a pipeline of drug candidates, including Aumolertinib, Sugemalimab, Lerociclib, and EQ176, targeting various forms of cancer. The company aims to disrupt the traditional pharmaceutical pricing model by offering its medicines at more affordable prices.
What are the main risks for EQRXW?
The main risks for EQRXW include the inherent uncertainties of pharmaceutical development, such as clinical trial failures or delays. Regulatory hurdles and potential rejection of drug submissions also pose significant risks. Competition from established pharmaceutical companies with greater resources and existing therapies is another key challenge. Pricing pressures and reimbursement challenges in the healthcare market could also impact EQRx's ability to achieve its financial goals. These risks are typical for biotechnology companies in the drug development space.
What are the key factors to evaluate for EQRXW?
EQRx, Inc. (EQRXW) holds an AI score of 47/100 (low). P/E: 5.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does EQRXW data refresh on this page?
EQRXW prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EQRXW's recent stock price performance?
EQRx, Inc. (EQRXW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug pipeline targeting significant unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EQRXW overvalued or undervalued right now?
EQRx, Inc. (EQRXW) trades at 5.4x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying EQRXW?
Before investing in EQRx, Inc. (EQRXW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding EQRXW to a portfolio?
Key strength of EQRx, Inc. (EQRXW): Innovative drug pipeline targeting significant unmet medical needs. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- AI analysis is pending and may provide additional insights.